After a relatively quiet 2021, sector analysts agree that 2022 looks set for a major upturn in merger activity – and not least because the 18 biggest pharma players will have amassed around $538bn to spend by the end of the year.
That was the calculation made by Jeffrey Porges, senior analyst at SVB Leerink in a note in early December 2021,...








